These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 33780898)

  • 1. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
    Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
    Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
    Wang M; Lu J; Wang M; Yang CY; Wang S
    J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of Pyrido[1,2-a]pyrimidin-4-one derivatives as novel allosteric SHP2 inhibitors.
    Zhang L; Ma W; Chen Y; Chen Z; Wang F; Xu Y
    Bioorg Chem; 2024 Oct; 151():107661. PubMed ID: 39067422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
    Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
    Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
    Tang K; Jia YN; Yu B; Liu HM
    Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
    Lier S; Sellmer A; Orben F; Heinzlmeir S; Krauß L; Schneeweis C; Hassan Z; Schneider C; Patricia Gloria Schäfer A; Pongratz H; Engleitner T; Öllinger R; Kuisl A; Bassermann F; Schlag C; Kong B; Dove S; Kuster B; Rad R; Reichert M; Wirth M; Saur D; Mahboobi S; Schneider G
    Bioorg Chem; 2022 Feb; 119():105505. PubMed ID: 34838332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
    Yang K; Song Y; Xie H; Wu H; Wu YT; Leisten ED; Tang W
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2493-2497. PubMed ID: 29871848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
    Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
    Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
    Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
    J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).
    Chen Y; Yuan X; Tang M; Shi M; Yang T; Liu K; Deng D; Chen L
    Bioorg Chem; 2022 Feb; 119():105508. PubMed ID: 34959180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Degradation of the Oncogenic Phosphatase SHP2.
    Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
    Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
    Zhang F; Wu Z; Chen P; Zhang J; Wang T; Zhou J; Zhang H
    Bioorg Med Chem; 2020 Jan; 28(1):115228. PubMed ID: 31813613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
    Mitra R; Ayyannan SR
    ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors.
    Luo R; Wang Z; Luo D; Qin Y; Zhao C; Yang D; Lu T; Zhou Z; Huang Z
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2170-2182. PubMed ID: 34749564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.
    Ma C; Kang D; Gao P; Zhang W; Wu X; Xu Z; Han H; Zhang L; Cai Y; Wang Y; Wang Y; Long W
    J Med Chem; 2024 Aug; 67(16):13534-13549. PubMed ID: 39110625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
    Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
    Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.